Waldencast shares rise 10.97% intraday after Obagi partners with VIO Med Spa on ALOHA Program for real-world evidence.

Waldencast surged 10.97% intraday trading following the announcement of a collaboration with VIO Med Spa under the ALOHA MagIQ program to generate real-world evidence for Obagi® saypha® MagIQ™ hyaluronic acid filler. The partnership, highlighted by VIO’s clinical expertise and national scalability, aims to evaluate the product’s performance and patient outcomes across multiple locations. The initiative aligns with Waldencast’s strategy to advance aesthetics solutions through evidence-based innovation and operational scale, reinforcing investor confidence in the company’s growth potential in the competitive med spa market. The news, emphasizing clinical excellence and market expansion, directly supported the sharp intraday price increase.